Risk of ovarian cancer after treatment for infertility

Giuseppe Del Priore; Kathleen Robischon; William R. Phipps; Robert Kurman; Edward E. Wallach; Howard A. Zacur; Samuel Shapiro; Mary Anne Rossing; Janet R. Daling; Noel S. Weiss; Daniel W. Cramer; Patricia Hartge; Philip C. Nasca; Alice S. Whittemore

doi:10.1056/NEJM199505113321912

Risk of ovarian cancer after treatment for infertility

Giuseppe Del Priore, Kathleen Robischon, William R. Phipps, Robert Kurman, Edward E. Wallach, Howard A. Zacur, Samuel Shapiro, Mary Anne Rossing, Janet R. Daling, Noel S. Weiss, Daniel W. Cramer, Patricia Hartge, Philip C. Nasca, Alice S. Whittemore

School of Medicine

Research output: Contribution to journal › Letter › peer-review

22 Scopus citations

Abstract

To the Editor: The article by Rossing et al. (Sept. 22 issue)¹ may have generated undue anxiety in many women undergoing treatment for infertility. Although this study does prompt some interesting hypotheses about the future risks of ovarian cancer in patients with ovulatory dysfunction, it does not convincingly link any risk to the use of clomiphene. There are several confounding variables and biases that weaken the validity of the authors’ conclusions. Patients undergoing treatment for infertility, especially those who take medication to induce ovulation, undergo far more surveillance with ultrasound studies than other patients, solely because of their treatment. Furthermore,.

Original language	English (US)
Pages (from-to)	1300-1302
Number of pages	3
Journal	New England Journal of Medicine
Volume	332
Issue number	19
DOIs	https://doi.org/10.1056/NEJM199505113321912
State	Published - May 11 1995

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJM199505113321912

Cite this

@article{3dee273d6cae489ead93c313e5c81e42,

title = "Risk of ovarian cancer after treatment for infertility",

abstract = "To the Editor: The article by Rossing et al. (Sept. 22 issue)1 may have generated undue anxiety in many women undergoing treatment for infertility. Although this study does prompt some interesting hypotheses about the future risks of ovarian cancer in patients with ovulatory dysfunction, it does not convincingly link any risk to the use of clomiphene. There are several confounding variables and biases that weaken the validity of the authors{\textquoteright} conclusions. Patients undergoing treatment for infertility, especially those who take medication to induce ovulation, undergo far more surveillance with ultrasound studies than other patients, solely because of their treatment. Furthermore,.",

author = "{Del Priore}, Giuseppe and Kathleen Robischon and Phipps, {William R.} and Robert Kurman and Wallach, {Edward E.} and Zacur, {Howard A.} and Samuel Shapiro and Rossing, {Mary Anne} and Daling, {Janet R.} and Weiss, {Noel S.} and Cramer, {Daniel W.} and Patricia Hartge and Nasca, {Philip C.} and Whittemore, {Alice S.}",

year = "1995",

month = may,

day = "11",

doi = "10.1056/NEJM199505113321912",

language = "English (US)",

volume = "332",

pages = "1300--1302",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "19",

}

TY - JOUR

T1 - Risk of ovarian cancer after treatment for infertility

AU - Del Priore, Giuseppe

AU - Robischon, Kathleen

AU - Phipps, William R.

AU - Kurman, Robert

AU - Wallach, Edward E.

AU - Zacur, Howard A.

AU - Shapiro, Samuel

AU - Rossing, Mary Anne

AU - Daling, Janet R.

AU - Weiss, Noel S.

AU - Cramer, Daniel W.

AU - Hartge, Patricia

AU - Nasca, Philip C.

AU - Whittemore, Alice S.

PY - 1995/5/11

Y1 - 1995/5/11

N2 - To the Editor: The article by Rossing et al. (Sept. 22 issue)1 may have generated undue anxiety in many women undergoing treatment for infertility. Although this study does prompt some interesting hypotheses about the future risks of ovarian cancer in patients with ovulatory dysfunction, it does not convincingly link any risk to the use of clomiphene. There are several confounding variables and biases that weaken the validity of the authors’ conclusions. Patients undergoing treatment for infertility, especially those who take medication to induce ovulation, undergo far more surveillance with ultrasound studies than other patients, solely because of their treatment. Furthermore,.

AB - To the Editor: The article by Rossing et al. (Sept. 22 issue)1 may have generated undue anxiety in many women undergoing treatment for infertility. Although this study does prompt some interesting hypotheses about the future risks of ovarian cancer in patients with ovulatory dysfunction, it does not convincingly link any risk to the use of clomiphene. There are several confounding variables and biases that weaken the validity of the authors’ conclusions. Patients undergoing treatment for infertility, especially those who take medication to induce ovulation, undergo far more surveillance with ultrasound studies than other patients, solely because of their treatment. Furthermore,.

UR - http://www.scopus.com/inward/record.url?scp=0029066977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029066977&partnerID=8YFLogxK

U2 - 10.1056/NEJM199505113321912

DO - 10.1056/NEJM199505113321912

M3 - Letter

C2 - 7772146

AN - SCOPUS:0029066977

SN - 0028-4793

VL - 332

SP - 1300

EP - 1302

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 19

ER -

Risk of ovarian cancer after treatment for infertility

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this